Drug Oncology

Imbruvica

Payments companies reported to CMS as associated with Imbruvica. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.0Massociated payments (2023-2025)

13,195clinicians with associated payments

9companies reporting

By year

2023 $2.0M

2024 $596K

2025 $438K

Payments reported as associated with Imbruvica, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $1.5M

Nurse Practitioner $286K

Medical Oncology $278K

Family $249K

Hematology (Internal Medicine) $152K

Physician Assistant $133K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Imbruvica

These are the largest totals companies reported as associated with Imbruvica. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Asad Dean	Fort Worth, TX	Hematology & Oncology	$127,182.46
Ilan Shapira	New York, NY	Hematology & Oncology	$76,189.92
Jarrod Holmes	Santa Rosa, CA	Hematology & Oncology	$74,376.04
Nakhle Saba	Baton Rouge, LA	Hematology & Oncology	$64,190.54
Ruemu Birhiray	Indianapolis, IN	Hematology & Oncology	$58,894.19
Bachar Dergham	Cleveland, OH	Hematology & Oncology	$47,268.28
John Allan	New York, NY	Hematology & Oncology	$45,282.59
Saeed Sadeghi	Santa Monica, CA	Hematology & Oncology	$44,841.23
Ryan Jacobs	Charlotte, NC	Hematology (Internal Medicine)	$42,577.91
Rhonda Hewitt	Stanford, CA	Nurse Practitioner	$40,785.81

Prescribed Imbruvica?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.